is an autoantibody seen in antiphospholipid syndrome that yields a falsely-elevated prothrombin time.
USMLE® Step 1 style questions USMLE
USMLE® Step 2 style questions USMLE
A 28-year-old gravida 3, para 0 female who comes to the office for a preconception visit. She has previously suffered recurrent pregnancy losses at 8, 10, and 12 weeks of gestation, respectively. After a thorough workup after her third pregnancy loss, she was diagnosed with antiphospholipid syndrome. She has not experienced any thrombotic events. She wishes to get pregnant again is concerned that she will miscarry again. Which of the following is most likely the appropriate treatment regimen for this patient?
In antiphospholipid syndrome, individuals produce antiphospholipid antibodies, which attack the phospholipids in the cell membrane of their own cells, or attack proteins that are bound to those phospholipids.
So antiphospholipid syndrome, or APS, is an autoimmune disease.
Antiphospholipid syndrome can be primary or secondary. Primary antiphospholipid syndrome occurs by itself, whereas secondary antiphospholipid syndrome occurs with other autoimmune diseases, especially systemic lupus erythematosus.
And just like most autoimmune diseases, antiphospholipid syndrome is more common in young females.
The exact cause of antiphospholipid syndrome isn’t known, but there are some known genetic and environmental factors.
But the presence of the mutated HLA-DR7 gene alone isn’t enough to develop antiphospholipid syndrome - an environmental trigger must also be present.
There’s a variety of potential triggers - some common ones include infections - like syphilis, hepatitis C, HIV, and malaria - drugs, like some cardiovascular drugs - including procainamide, quinidine, propranolol, and hydralazine - or antipsychotic drugs like phenytoin and chlorpromazine.
The main antiphospholipid antibody is anti-beta2-glycoprotein I, which targets the protein beta2-glycoprotein I, also called apolipoprotein H.
This protein binds to phospholipids and inhibits agglutination which is when platelets clump together to form blood clots.
So when anti-beta2-glycoprotein I binds beta2-glycoprotein I, it’s not free to do its job, and that leads to clot formation.
Another antiphospholipid antibody is anti-cardiolipin, which targets a lipid in the inner mitochondrial membrane called cardiolipin which binds beta2-glycoprotein I.
Autoantibodies might also target blood components.
If platelets are targeted, it can lead to thrombocytopenia, and if red blood cells are targeted it can lead to anemia.
So the antiphospholipid antibodies lead to a hypercoagulable state, meaning that they cause thrombosis or blood clots to form within arteries and veins.
In addition, individuals might develop Libman-Sacks endocarditis, which is where vegetations form, which are a mixture of immune cells and blood clots - usually on the mitral valve.
Venous thrombosis is more common in females, and typically presents as a deep vein thrombosis.
Sometimes, a part of the main clot may break free and become an embolus, which is where a blood clot travels downstream.
Since lung capillaries are very small, this embolus could get stuck, causing a pulmonary embolism.
This is a life-threatening situation because it literally blocks blood from getting into the lungs to pick up oxygen.
Another organ with very small capillaries is the kidneys, so individuals might develop renal failure.